MBX Biosciences (NYSE:MBX) Earns Outperform Rating from Analysts at Oppenheimer

Oppenheimer assumed coverage on shares of MBX Biosciences (NYSE:MBX) in a research report sent to investors on Wednesday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $38.00 target price on the stock.

A number of other equities analysts have also recently commented on MBX. Citizens Jmp started coverage on shares of MBX Biosciences in a research note on Thursday, April 10th. They issued an “outperform” rating and a $38.00 price objective for the company. JMP Securities began coverage on shares of MBX Biosciences in a report on Thursday, April 10th. They issued a “market outperform” rating and a $38.00 target price for the company. Finally, Guggenheim restated a “buy” rating and set a $44.00 target price on shares of MBX Biosciences in a research report on Thursday, April 10th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $37.57.

MBX Biosciences Trading Down 3.6%

NYSE MBX opened at $11.75 on Wednesday. MBX Biosciences has a one year low of $4.81 and a one year high of $27.50. The stock has a 50 day moving average price of $11.80 and a 200-day moving average price of $10.61.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. purchased a new position in MBX Biosciences in the 4th quarter worth about $1,720,000. Nuveen Asset Management LLC purchased a new stake in shares of MBX Biosciences in the 4th quarter worth $267,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in MBX Biosciences during the 4th quarter worth about $117,000. Citadel Advisors LLC grew its holdings in MBX Biosciences by 62.5% during the 4th quarter. Citadel Advisors LLC now owns 220,330 shares of the company’s stock worth $4,061,000 after acquiring an additional 84,722 shares in the last quarter. Finally, Deutsche Bank AG bought a new position in MBX Biosciences during the 4th quarter worth about $80,000.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.